美西律的临床药理学。
The clinical pharmacology of mexiletine.
作者信息
Campbell N P, Kelly J G, Adgey A A, Shanks R G
出版信息
Br J Clin Pharmacol. 1978 Aug;6(2):103-8. doi: 10.1111/j.1365-2125.1978.tb00833.x.
Abstract
- Mexiletine was given to 156 patients by intravenous or oral routes of administration. 2. There was great interpatient variation in kinetics and plasma concentrations with both routes of administration. 3. The mean volume of distribution was 6.63 l/kg. The mean plasma elimination haf-life after chronic oral therapy was 11.31 h. 4. Plasma concentrations between 0.75 and 2.00 microgram/ml were usually effective. Within this therapeutic range severe side effects were uncommon. 5. Plasma concentrations within this range were achieved in 72% of patients when doses of 10--14 mg-1 kg-1 day were given orally.
摘要
- 美西律通过静脉或口服途径给予156例患者。2. 两种给药途径在动力学和血浆浓度方面患者间存在很大差异。3. 平均分布容积为6.63升/千克。慢性口服治疗后的平均血浆消除半衰期为11.31小时。4. 血浆浓度在0.75至2.00微克/毫升之间通常有效。在此治疗范围内严重副作用不常见。5. 当口服剂量为10 - 14毫克/千克/天时，72%的患者达到了此范围内的血浆浓度。
相似文献
1
The clinical pharmacology of mexiletine.美西律的临床药理学。
Br J Clin Pharmacol. 1978 Aug;6(2):103-8. doi: 10.1111/j.1365-2125.1978.tb00833.x.
2
Plasma mexiletine concentrations following combined oral and intramuscular administration.
Eur J Clin Pharmacol. 1981 Mar;19(4):301-4. doi: 10.1007/BF00562808.
3
Dose independent pharmacokinetics of mexiletine in healthy volunteers.美西律在健康志愿者体内的非剂量依赖性药代动力学。
Br J Clin Pharmacol. 1986 Mar;21(3):319-21. doi: 10.1111/j.1365-2125.1986.tb05196.x.
4
Mexiletine in normal volunteers.美西律在正常志愿者中的应用。
Br J Clin Pharmacol. 1978 Oct;6(4):372-3. doi: 10.1111/j.1365-2125.1978.tb00868.x.
5
Pharmacokinetics of mexiletine in renal insufficiency.
Acta Cardiol Suppl. 1980(25):55-65.
6
A schedule for combined intravenous and oral dosing with mexiletine.
J Int Med Res. 1979;7(2):162-4. doi: 10.1177/030006057900700209.
7
Adaptation of the dose of mexiletine according to pharmacokinetic data.
Acta Cardiol Suppl. 1980(25):67-73.
8
Mexiletine in the management of ventricular dysrhythmias.
Eur J Cardiol. 1977 Dec;6(4):245-58.
9
[Kinetics of mexiletine distribution in the rat].
Arch Farmacol Toxicol. 1983 Apr;9(1):65-76.
10
Development of a dosage scheme for simultaneous intravenous and oral administration of mexiletine.
Postgrad Med J. 1977;53 Suppl 1:128-33.
引用本文的文献
1
Human-induced pluripotent stem cell-derived cardiomyocytes: Cardiovascular properties and metabolism and pharmacokinetics of deuterated mexiletine analogs.人诱导多能干细胞衍生的心肌细胞：氘代美西律类似物的心血管特性、代谢和药代动力学。
Pharmacol Res Perspect. 2021 Aug;9(4):e00828. doi: 10.1002/prp2.828.
2
Interactions of Mexiletine with Novel Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis.美西律与新型抗癫痫药物在小鼠最大电休克试验中的相互作用：立体药理学分析。
Neurochem Res. 2018 Oct;43(10):1887-1896. doi: 10.1007/s11064-018-2606-8. Epub 2018 Aug 16.
3
Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine.抗心律失常药美西律及其代谢物 m-羟基美西律对 hERG 钾通道的抑制作用。
Pharmacol Res Perspect. 2015 Oct;3(5):e00160. doi: 10.1002/prp2.160. Epub 2015 Jul 31.
4
Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents.美西律主要代谢产物对骨骼肌钠电流的药理活性评估。
Br J Pharmacol. 2006 Oct;149(3):300-10. doi: 10.1038/sj.bjp.0706867. Epub 2006 Aug 21.
5
Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers.CYP2D6*10对健康成年志愿者美西律药代动力学的影响。
Eur J Clin Pharmacol. 2003 Sep;59(5-6):395-9. doi: 10.1007/s00228-003-0656-5. Epub 2003 Aug 23.
6
Therapeutic drug monitoring of antiarrhythmic drugs.抗心律失常药物的治疗药物监测
Clin Pharmacokinet. 2003;42(7):647-63. doi: 10.2165/00003088-200342070-00004.
7
Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes.CYP2D6*10等位基因对人肝微粒体代谢美西律的影响。
Br J Clin Pharmacol. 2001 Jul;52(1):100-3. doi: 10.1046/j.0306-5251.2001.01411.x.
8
Clinical pharmacokinetics of mexiletine.美西律的临床药代动力学。
Clin Pharmacokinet. 1999 Nov;37(5):361-84. doi: 10.2165/00003088-199937050-00002.
9
Involvement of CYP1A2 in mexiletine metabolism.CYP1A2参与美西律的代谢。
Br J Clin Pharmacol. 1998 Jul;46(1):55-62. doi: 10.1046/j.1365-2125.1998.00048.x.
10
Plasma mexiletine concentrations following combined oral and intramuscular administration.
Eur J Clin Pharmacol. 1981 Mar;19(4):301-4. doi: 10.1007/BF00562808.
本文引用的文献
1
Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine.
J Pharm Pharmacol. 1973 Jul;25(7):550-3. doi: 10.1111/j.2042-7158.1973.tb09155.x.
2
St-segment displacement and early hospital discharge in acute myocardial infarction.
Lancet. 1973 Dec 8;2(7841):1284-8. doi: 10.1016/s0140-6736(73)92868-7.
3
Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.美西律（Kö 1173）用于室性心律失常的治疗。
Lancet. 1973 Aug 25;2(7826):404-7. doi: 10.1016/s0140-6736(73)92271-x.
4
Treatment of ventricular arrhythmias with mexiletine (Kö 1173).美西律（Kö 1173）治疗室性心律失常
Lancet. 1973 Aug 25;2(7826):399-404. doi: 10.1016/s0140-6736(73)92270-8.
5
Drug therapy. Clinical Pharmacokinetics (first of two parts).药物治疗。临床药代动力学（两部分中的第一部分）。
N Engl J Med. 1975 Oct 2;293(14):702-5. doi: 10.1056/NEJM197510022931406.
6
Absorption, distribution and elimination of mexiletine.
Postgrad Med J. 1977;53 Suppl 1:50-5.
7
Measurement of plasma mexiletine concentrations.
Postgrad Med J. 1977;53 Suppl 1:48-9.
8
Oral dosage schedules for mexiletine.
Postgrad Med J. 1977;53 Suppl 1:155-7.
9
Long-term treatment of ventricular arrhythmias with oral mexiletine.
Am Heart J. 1976 Jan;91(1):58-65. doi: 10.1016/s0002-8703(76)80435-8.
10
Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction.
Lancet. 1975 Jun 7;1(7919):1257-60. doi: 10.1016/s0140-6736(75)92548-9.
Zotero 插件